93 results
DEFA14A
VIR
Vir Biotechnology Inc
14 May 24
Additional proxy soliciting materials
4:05pm
the COVID-19 pandemic but currently no revenue stream 1) Sotrovimab has obtained emergency authorization, temporary authorization or market approval (under
8-K
EX-99.1
VIR
Vir Biotechnology Inc
2 May 24
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results
4:09pm
arisen since the 1918 flu pandemic. VIR-2482 is designed as a prophylactic for influenza A. VIR-2482 incorporates Xencor’s Xtend™ and was identified … demonstrate the antibody’s breadth and potency against all major strains of seasonal and pandemic influenza viruses and support the potential
8-K
EX-99.1
gilhb06a zew
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
8-K
mmmcw
13 Dec 23
Cost Associated with Exit or Disposal Activities
4:06pm
S-3ASR
zmk 90u0o75zl
3 Nov 23
Automatic shelf registration
4:33pm
8-K
EX-99.1
kb9u7b1
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
8-K
pzx92er6phc2 cu
3 Oct 23
Entry into a Material Definitive Agreement
8:01am
8-K
EX-99.1
rslrbvv4
3 Aug 23
Vir Biotechnology Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:14pm
8-K
qsb8 anjav
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am
8-K
EX-99.1
iv1e1zl 5i
20 Jul 23
Vir Biotechnology Announces Topline Data from Phase 2 PENINSULA Trial Evaluating
8:04am
8-K
EX-99.1
eujfi28ovt37vwvp0g
4 May 23
Vir Biotechnology Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:16pm